A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate. * T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells. * A T-cell is a type of white blood cell, which are cells that help the body fight infection. * An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of combining gocatamig and I-DXd and if people tolerate them together * If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak płuca drobnokomórkowy w zaawansowanym stadium.
- •Osoby, które nie miały wcześniej żadnego leczenia systemowego na ten typ raka (w niektórych przypadkach).
- •Możliwość dostarczenia próbki tkanki guza lub nowo pobranej biopsji.
- •Wykryte zmiany nowotworowe widoczne w badaniach obrazowych.
✗ Disqualifies
- •Obecność płynu w jamie opłucnej, osierdziowej lub otrzewnowej, który wymaga częstego usuwania.
- •Historia lub obecne problemy z chorobami płuc niezwiązanymi z nowotworem, jak np. zapalenie śródmiąższowe płuc.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (37)
Providence Medical Foundation ( Site 0124)
Santa Rosa, United States
Orlando Health Cancer Institute ( Site 0108)
Orlando, United States
Saint Elizabeth Medical Center Edgewood ( Site 0112)
Edgewood, United States
Washington University School of Medicine ( Site 0134)
St Louis, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101)
Hackensack, United States
Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107)
Portland, United States
Avera Cancer Institute- Research ( Site 0104)
Sioux Falls, United States
The University of Tennessee Medical Center ( Site 0120)
Knoxville, United States
Lt. Col. Luke Weathers, Jr. VA Medical Center ( Site 0133)
Memphis, United States
SCRI Oncology Partners ( Site 7000)
Nashville, United States
Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113)
Houston, United States
University of Virginia Health System ( Site 0122)
Charlottesville, United States
CEMIC ( Site 1903)
Caba., Argentina
Hospital Austral ( Site 1901)
Pilar, Argentina
Sanatorio Parque ( Site 1900)
Rosario, Argentina
FALP ( Site 0200)
Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 0202)
Santiago, Chile
Bradfordhill ( Site 0201)
Santiago, Chile
Beijing Cancer Hospital ( Site 1604)
Beijing, China
Southern Medical University Nanfang Hospital ( Site 1608)
Guangzhou, China
Jiangmen Central Hospital ( Site 1611)
Jiangmen, China
The First Affiliated Hospital of Nanchang University ( Site 1610)
Nanchang, China
Shanghai East Hospital ( Site 1600)
Shanghai, China
Sichuan Cancer hospital. ( Site 1609)
Chengdu, China
The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 1602)
Hangzhou, China
Taizhou Hospital of Zhejiang Province ( Site 1601)
Taizhou, China
Universitaetsklinikum Jena ( Site 0403)
Jena, Germany
Rambam Health Care Campus ( Site 0602)
Haifa, Israel
Sheba Medical Center ( Site 0601)
Ramat Gan, Israel
Seoul National University Hospital ( Site 1402)
Seoul, South Korea
Severance Hospital Yonsei University Health System ( Site 1403)
Seoul, South Korea
Asan Medical Center ( Site 1404)
Seoul, South Korea
Samsung Medical Center ( Site 1401)
Seoul, South Korea
Hospital San Pedro ( Site 1004)
Logroño, Spain
Hospital Universitario Insular de Gran Canaria ( Site 1002)
Las Palmas de Gran Canaria, Spain
Faculty of Medicine Siriraj Hospital ( Site 3000)
Bangkoknoi, Thailand
Songklanagarind hospital ( Site 3001)
Hat Yai, Thailand
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.